Neuroprotective effects of PEP-1-carbonyl reductase 1 against oxidative-stress-induced ischemic neuronal cell damage

Human carbonyl reductase 1 (CBR1) is a member of the NADPH-dependent short-chain dehydrogenase/reductase superfamily that is known to play an important role in neuronal cell survival via its antioxidant function. Oxidative stress is one of the major causes of degenerative disorders including ischemia. However, the role CBR1 plays with regard to ischemic injury is as yet poorly understood. Protein transduction domains such as PEP-1 are well known and now commonly used to deliver therapeutic proteins into cells. In this study, we prepared PEP-1–CBR1 protein and examined whether it protects against oxidative-stress-induced neuronal cell damage. PEP-1–CBR1 protein was efficiently transduced into hippocampal neuronal HT-22 cells and protected against hydrogen peroxide (H₂O₂)-induced neuronal cell death. Transduced PEP-1–CBR1 protein drastically inhibited H₂O₂-induced reactive oxygen species production, the oxidation of intracellular macromolecules, and the activation of mitogen-activated protein kinases, as well as cellular apoptosis. Furthermore, we demonstrated that transduced PEP-1–CBR1 protein markedly protected against neuronal cell death in the CA1 region of the hippocampus resulting from ischemic injury in an animal model. In addition, PEP-1–CBR1 protein drastically reduced activation of glial cells and lipid peroxidation in an animal model. These results indicate that PEP-1–CBR1 protein significantly protects against oxidative-stress-induced neuronal cell death in vitro and in vivo. Therefore, we suggest that PEP-1–CBR1 protein may be a therapeutic agent for the treatment of ischemic injuries as well as oxidative-stress-induced cell damage and death.     

Bone marrow mesenchymal stem cell therapy regulates gut microbiota to improve post-stroke neurological function recovery in rats

BACKGROUNDAs a cellular mode of therapy, bone marrow mesenchymal stem cells (BMSCs) are used to treat stroke. However, their mechanisms in stroke treatment have not been established. Recent evidence suggests that regulation of dysregulated gut flora after stroke affects stroke outcomes.AIMTo investigate the effects of BMSCs on gut microbiota after ischemic stroke.METHODSA total of 30 Sprague-Dawley rats were randomly divided into three groups, including sham operation control group, transient middle cerebral artery occlusion (MCAO) group, and MCAO with BMSC treatment group. The modified Neurological Severity Score (mNSS), beam walking test, and Morris water maze test were used to evaluate neurological function recovery after BMSC transplantation. Nissl staining was performed to elucidate on the pathology of nerve cells in the hippocampus. Feces from each group of rats were collected and analyzed by 16s rDNA sequencing.RESULTSBMSC transplantation significantly reduced mNSS (P < 0.01). Rats performed better in the beam walking test in the BMSC group than in the MCAO group (P < 0.01). The Morris water maze test revealed that the BMSC treatment group exhibited a significant improvement in learning and memory. Nissl staining for neuronal damage assessment after stroke showed that in the BMSC group, cells were orderly arranged with significantly reduced necrosis. Moreover, BMSCs regulated microbial structure composition. In rats treated with BMSCs, the abundance of potential short-chain fatty acid producing bacteria and Lactobacillus was increased.CONCLUSIONBMSC transplantation is a potential therapeutic option for ischemic stroke, and it promotes neurological functions by regulating gut microbiota dysbiosis.     

外源性H2S恢复缺氧后适应对衰老H9C2细胞的保护作用及机制

目的：探讨外源性硫化氢（H₂S）恢复缺氧后适应对衰老H9C2细胞的保护作用及相关机制。方法：H9C2细胞（心肌细胞系）用30 μmol/L过氧化氢（H₂O₂）处理2 h后再培养3 d,诱导生成衰老细胞。衰老H9C2细胞被随机分5组（n=8）：正常组（Control）、缺氧/复氧组（H/R）、H/R+NaHS组、缺氧后适应（PC）组、PC+NaHS组。缺氧/复氧（H/R）模型：衰老H9C2细胞用缺氧液（无血清、无糖培养基,pH=6.8）培养3 h,然后正常培养6 h;缺氧后适应（PC）模型：方法同H/R模型,缺氧结束复氧前连续进行3次5 min间隔的复氧/再缺氧处理,随后复氧6 h。ELISA试剂盒分别检测大鼠晚期糖基化终末产物（AGEs）含量和caspase-3活性;CCK-8试剂盒检测细胞活力;DCFH-DA染色检测活性氧（ROS）水平;Hoechst 33342染色检测细胞凋亡率;Real-time PCR检测相关基因mRNA水平。结果：30 μmol/L H₂O₂可诱导H9C2细胞衰老但不会导致其凋亡;与Control组比较,H/R和PC均降低细胞活力,增加细胞凋亡率、ROS水平及caspase-3、caspase-9和Bcl-2 mRNA水平（P<0.01）;且PC组与H/R组比较,上述指标变化无明显差异;在H/R和PC组加入NaHS,可显著提高细胞活力,降低细胞凋亡率和氧化应激;PC+NaHS对上述指标的作用明显强于H/R+NaHS。结论：外源性H₂S能够恢复PC对衰老H9C2细胞的保护作用,其机制与抑制氧化应激和细胞凋亡有关。     

神经生长因子多药联合治疗缺血性视神经病变患者的临床疗效

目的:研究神经生长因子(NGF)多药联合治疗缺血性视神经病变(AION)患者的临床疗效。方法:选择2011年5月至2013年5月在我院接受治疗的AION患者100例(100只眼),根据数字表法随机分成观察组(50例,50只眼)及对照组(50例,50只眼)。对照组给予扩血管药和维生素神经营养性药物控制高血压或糖尿病等合并症,视情况给予糖皮质类激素治疗,观察组在此基础上另给予NGF药物治疗。对比两组疗效、对数视力、视野平均缺损值(MD)及视敏度通过图形视觉诱发电位(P-VEP100)P100波的潜伏期,观察两组不良反应。结果:观察组的总有效率为90.00%(45/50),显著高于对照组的74.00%(37/50),差异有统计学意义(P0.05)。两组在治疗后的对数视力、视野MD以及P-VEP100均有改善,但观察组的改善幅度显著大于对照组,差异有统计学意义(P0.05)。两组不良反应发生率差异无统计学意义(P0.05)。结论:NGF多药联合治疗AION患者疗效更佳,可促进患者视觉功能恢复,值得临床上推广使用。     

Possible Involvement of Extracellular ATP-P2Y Purinoceptor Signaling in Ischemia-induced Tolerance of Astrocytes in Culture

Extracellular adenosine 5′-triphosphate (ATP) activates specific G protein-coupled purinoceptors (P2Y), and ATP-P2Y signaling pathways induces intracellular Ca²⁺ mobilization resulting in changes in the gene expression of a variety of proteins in astrocytes. This study investigated whether the exposure of cultured astrocytes to sublethal ischemia produced resistance to subsequent lethal ischemic stress, and if so, whether the extracellular ATP-P2Y signaling pathways were responsible for the tolerance. Ischemia-like insults, sublethal oxygen-glucose deprivation (sOGD), produced tolerance to subsequent lethal OGD stress in cultured astrocytes. Early during reperfusion after sOGD, the amount of extracellular ATP and the expression of both P2Y₁ and P2Y₂ receptors were increased, leading to enhanced activation of the extracellular ATP-P2Y signaling pathways. The occurrence of intracellular spontaneous Ca²⁺ oscillations was also increased. In addition, sOGD treatment enhanced the expression of the phosphorylated form of extracellular signal-regulated protein kinases 1 and 2 (p-ERK 1/2), and treatment with an inhibitor of ERK significantly attenuated the sOGD-induced ischemic tolerance of astrocytes.     

Therapeutic potential of nitric oxide synthase inhibitor from natural sources for the treatment of ischemic stroke

Nitric oxide (NO) is one of the major signalling molecules in the mammalian body playing critical role in regulation of blood pressure, cardiovascular disease including stroke, immune activation, neuronal and cell communication. Moreover, hyper production of NO by the activity of nitric oxide synthase (NOS) involved in neuropathic pain, neurodegenerative disorders and stroke. Hence, the search on small molecules from the natural sources for the inhibition of NOS is desirable in therapeutic point of view. The elevated level of NO caused by NOS enzyme become a novel target in finding new inhibitors from natural sources as antistroke agents. The present study focuses on the molecular docking of quercetin and its analogues against NOS. The active site of the enzyme was docked with the ligand and pharmacological properties were analysed. From this result, we suggest the therapeutic property of quercetin and its analogues against NOS.     

Fenobam promoted the neuroprotective effect of PEP-1-FK506BP following oxidative stress by increasing its transduction efficiency

We examined the ways in which fenobam could promote not only the transduction of PEP-1-FK506BP into cells and tissues but also the neuroprotective effect of PEP-1-FK506BP against ischemic damage. Fenobam strongly enhanced the protective effect of PEP-1-FK506BP against H₂O₂-induced toxicity and DNA fragmentation in C6 cells. In addition, combinational treatment of fenobam with PEP-1-FK506BP significantly inhibited the activation of Akt and MAPK induced by H₂O₂, compared to treatment with PEP-1-FK506BP alone. Interestingly, our results showed that fenobam significantly increased the transduction of PEP-1-FK506BP into both C6 cells and the hippocampus of gerbil brains. Subsequently, a transient ischemic gerbil model study demonstrated that fenobam pretreatment led to the increased neuroprotection of PEP-1-FK506BP in the CA1 region of the hippocampus. Therefore, these results suggest that fenobam can be a useful agent to enhance the transduction of therapeutic PEP-1-fusion proteins into cells and tissues, thereby promoting their neuroprotective effects. [BMB Reports 2013; 46(11): 561-566]     

MicroRNA在靶向治疗缺血性心脏病中的研究进展

MicroRNA（MiRNA,miR）通过调节信使RNA（mRNA）的表达,广泛参与心血管系统细胞的增殖、迁移、分化、凋亡等病理生理过程,在心血管系统疾病的发生发展过程中起着重要的调控作用。越来越多的研究表明,针对缺血性心血管疾病的发病机制,通过特异性调节miRNA的活性,抑制相关蛋白的表达,对各种缺血性心脏病具有显著的治疗作用。但目前开发miRNA靶向治疗药物尚缺乏大规模的临床试验研究,其有效性和安全性需进一步证实。本文旨在综述MicroRNA在靶向治疗缺血性心脏病中的研究进展,以期为开发MiRNA靶向治疗药物治疗缺血性心脏病提供更多的理论依据。     

缺血预处理通过激活自噬保护肾缺血-再灌注损伤

目的:探讨缺血预处理对缺血-再灌注所致急性肾损伤的保护作用与可能机制。方法:将健康雄性SD大鼠18只随机分为三组:假手术组(Sham组)、肾缺血组(I/R组)、实验组,Sham组大鼠开腹后游离左侧肾蒂血管,不夹闭,观察60 min关闭腹部。I/R组大鼠开腹后切除右肾,左肾蒂血管分离,观察15 min后用无损伤动脉夹持续夹闭左肾蒂血管45 min后,关闭腹部,恢复左肾血流。实验组开腹后切除切除右肾,左肾蒂血管分离,行4个循环夹闭左肾蒂血管1 min/再灌注4 min预处理后,无损伤动脉持续夹闭45 min,关闭腹部,恢复左肾血流。比较各组大鼠术后尿素氮值(Burea nitrogen,BUN)与肌酐值(Serum creatinine,SCR)水平,肾组织病理学评分及微管相关蛋白轻链3(Microtubule-associated protein l light chain 3,LC3)和自噬基因Beclin-1的表达。结果:所有大鼠在实验过程无死亡。I/R组、实验组再灌注后4 h、24 h的BUN与SCr值显著高于Sham组(P0.05),肾脏组织病理学评分显著高于Sham组(P0.05),实验组以上指标均显著低于I/R组(P0.05);I/R组LC3-Ⅱ/LC3-Ⅰ比值、Beclin-1相对表达量显著高于Sham组(P0.05),实验组以上指标均显著低于I/R组(P0.05)。实验组大鼠再灌注后24h LC3-Ⅱ/LC3-Ⅰ比值、Beclin-1相对表达量与肾组织病理学评分、BUN、SCr值呈显著相关性(P0.05)。结论:缺血预处理可能通过激活自噬,减轻缺血-再灌注所致急性肾损伤,并改善肾功能。